thumbnail image


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文


  • Home
  • About us 
    • Management
    • Living Innovation
    • Company presentation
  • Science 
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient 
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News 
    • News
    • Company presentation
  • Partners 
    • Careers
    • Collaboration
    • Contact us
  • …  
    • Home
    • About us 
      • Management
      • Living Innovation
      • Company presentation
    • Science 
      • Pipeline
      • xLink MAb platform
      • xLink BsAb platform
      • xLink MsAb platform
      • Publications
    • Patient 
      • Cancer Immunotherapy
      • LVGN6051
      • LVGN7409
      • LVGN3616
      • Resources
    • News 
      • News
      • Company presentation
    • Partners 
      • Careers
      • Collaboration
      • Contact us
  • English
     
    • English
    • 中文
  • Home
  • About us
    • Management
    • Living Innovation
    • Company presentation
  • Science
    • Pipeline
    • xLink MAb platform
    • xLink BsAb platform
    • xLink MsAb platform
    • Publications
  • Patient
    • Cancer Immunotherapy
    • LVGN6051
    • LVGN7409
    • LVGN3616
    • Resources
  • News
    • News
    • Company presentation
  • Partners
    • Careers
    • Collaboration
    • Contact us
  • 搜索
    该产品已经下线 返回主页
    • Immune-oncology Agonistic Antibodies

      Cross-linking (xLinkTM)Synthetic Biology

      Tumor-targeted Immune Activation

    • Clinical Development Candidates

      LVGN6051

      Next generation CD137/4-1BB agonistic monoclonal antibody

      LVGN6051 is designed to stimulate the proliferation and cytotoxicity of antitumor immune cells. Optimal efficacy and safety profile are achieved by the crosslinking dependent CD137 agonistic activity through FcγRIIB.

       

       

      LVGN7409

      Next generation CD40 agonistic monoclonal antibody

      CD40 activation by LVGN7409 promotes tumor antigen presentation and induction of cancer-fighting T cells, and "warm up" the immune-"cold" tumor microenvironment. Unique structure and functionality of LVGN7409 permits its higher tolerable dosage and broader clinical utility.

       

       

      LVGN3616

      Proprietary PD-1 blocking monoclonal antibody

      LVGN3616 blocks PD-1 pathway to unleash the "brake" of the immune responses against cancer.

       

    • Lyvgen xLinkAb platform

      xLinkAb Avidity Cross-linking Synthetic Biology

      xLinkMAb

      • Cross-linking monoclonal antibodies
      • Target activation dependent on FcγRIIB engagement

      xLinkBsAb

      • Cross-linking dependent bi-specific antibodies
      • Target activation dependent on binding to another antigen
       
       

      xLinkMsAb

      • Cross-linking multi-specific antibodies
      • New generation CD3 T cell engager with co-stimulation
      • IgG-like design
    • Lyvgen Shanghai

      Suite 317, Building 1, 351 Guoshoujing Road

      Lyvgen Shanghai

      Suite 601B, Building 8, 1043 Halei Road

      Lyvgen Suzhou

      Room 137, Building C36, 188 Dongping Street

      Inquiries

       

      General ------------------------------ ---Business Development----------------------------Employment--------------------------------------Clinical

      info@lyvgen.com  -----------------1 bd@lyvgen.com                  ------------ -----        careers@lyvgen.com    ------------------      clinical@lyvgen.com

       

      Phone +86 021-50663350

      Contact us on LinkedIn

      Copyright © 2022 LYVGEN BIOPHARMA. All Rights Reserved. Lyvgen website is designed to provide general information about the subject matter presented. The information presented does not, and is not intended to, provide medical advice.

    沪公网安备 31011502015346号
    |
    沪ICP备20018873号-2
      Home
      About us
      xLinkAb
      Contact us
    Lyvgen Biopharma Website 礼进生物 英文官网
    Lyvgen is a biotech company focused on developing novel therapies for cancer. Lyvgen’s xLinkAb™ functional platform creates agonist antibodies (Abs) with tumor-localized immunostimulatory activities by balancing multiple functions of candidate Abs.
    https://user-assets.sxlcdn.com/images/676507/FiTA8WK-FQRyXrQDyd-HDkY3tpfI.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
    Cookie的使用
    我们使用cookies来确保流畅的浏览体验。若继续,我们认为你接受使用cookies。
    了解更多